- Report
- April 2025
- 200 Pages
Global
From €7235EUR$7,950USD£6,203GBP
- Report
- June 2024
- 200 Pages
Global
From €7235EUR$7,950USD£6,203GBP
- Report
- February 2024
- 120 Pages
Asia Pacific
From €4505EUR$4,950USD£3,862GBP
- Clinical Trials
- April 2024
- 180 Pages
Global
From €2275EUR$2,500USD£1,951GBP
- Clinical Trials
- April 2024
- 40 Pages
Global
From €1138EUR$1,250USD£975GBP
- Report
- August 2022
Global
From €719EUR$790USD£616GBP
- Report
- August 2022
United States
From €1766EUR$1,940USD£1,514GBP
- Report
- February 2021
Global
From €2694EUR$2,960USD£2,309GBP
Liver Cirrhosis is a chronic liver disease caused by the accumulation of scar tissue in the liver. It is a progressive condition that can lead to liver failure and death. Treatment for liver cirrhosis includes lifestyle changes, medications, and in some cases, surgery. Medications used to treat liver cirrhosis include antiviral drugs, antibiotics, antifibrotic drugs, and immunosuppressants. These drugs are used to reduce inflammation, reduce the risk of infection, and slow the progression of the disease.
The Liver and Kidney Disorders Drugs market is a rapidly growing segment of the pharmaceutical industry. This market includes drugs used to treat a variety of liver and kidney disorders, including liver cirrhosis. These drugs are used to reduce inflammation, reduce the risk of infection, and slow the progression of the disease.
Some companies in the Liver Cirrhosis Drug market include AbbVie, Bristol-Myers Squibb, Gilead Sciences, Merck, and Pfizer. Show Less Read more